We aimed to investigate the discriminant ability of CSF Ng levels to distinguish between AD and FTLD pathology and between different stages within the same disease, the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum. Here, NRGN is linked to Alzheimer disease.